Lung cancer trial seeks optimal immunotherapy schedule around surgery
NCT ID NCT07554846
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. Participants will receive toripalimab either before surgery (neoadjuvant), after surgery (adjuvant), or both before and after surgery (perioperative), all combined with chemotherapy. The study aims to find which timing best prevents the cancer from returning over three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (an immunotherapy drug) combined with chemotherapy (pemetrexed and carboplatin or cisplatin)
- What this could lead to
- If successful, this could show the best timing for immunotherapy to prevent lung cancer from coming back after surgery, potentially improving survival rates.
- What could go wrong
- This is an early-stage trial in a specific lung cancer type, and results may not apply to all patients. Immunotherapy can cause immune-related side effects, and the added benefit over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-IIIA NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China